Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

Thumbnail

Beta-amyloid plaque progression is pinned to arterial stiffness

The ongoing deposition of beta-amyloid in the aging brain is related to central arterial stiffness, according to a study published online March 31 in JAMA Neurology.

Y-90 radioembolization effectively treats metastatic breast cancer

Breast cancer metastases that have spread to the liver have been found to be treated successfully with yttrium-90 (Y-90) radioembolization, which led to stabilized disease in 98.5 percent of liver tumors, according to procedings of the Society of Interventional Radiology's 39th Annual Scientific Meeting held March 22-27 in San Diego.

Thumbnail

ABY-025 affibody SPECT highlights HER2 status in breast cancer

First-in-human trial of Indium-111 ABY-025 affibody molecule SPECT imaging safely points out human epidermal growth factor receptor type 2 (HER2) expression in metastatic breast tumors, according to preliminary research published online March 24 in the Journal of Nuclear Medicine.

Thumbnail

Breast imaging with both FDG PET and MR provides additional information

Pretreatment PET with F-18 FDG as well as MR imaging provides useful diagnostic data, with PET showing a particular edge for prognosis, according to a study published online March 24 in the Journal of Nuclear Medicine.

Thumbnail

Lantheus Medical Imaging implicated in $6.2M tax settlement

The office of the New York attorney general, Eric T. Scheiderman, released a statement earlier this month naming Lantheus Medical Imaging and Bristol-Myers Squib in a $6.2 million settlement for failing to pay corporate income taxes in New York.

Thumbnail

PET points to neuroinflammation in chronic fatigue syndrome

The symptoms experienced by those who suffer from chronic fatigue may be related to acute inflammation in the brain, according to a PET study published March 24 in the Journal of Nuclear Medicine.

Global radiopharmaceutical market experiencing significant growth

The worldwide market for radiopharmaceuticals is expected to round out at a compound annual growth rate of 18.39 percent every year from 2012 through 2016, according to a report announced March 26 by research firm TechNavio.

Thumbnail

NeuroPhage gets $17M boost for brain therapeutics

Pharmaceutical company NeuroPhage has nailed $15 million in financing for therapeutic drugs for neurodegenerative disorders including Alzheimer’s disease and Parkinson's, the company announced March 25.